Menu Search
Equities

Jubilant Pharmova Ltd

JUBLPHARMA:NSI

Jubilant Pharmova Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,140.10
  • Today's Change4.60 / 0.41%
  • Shares traded71.47k
  • 1 Year change+171.45%
  • Beta1.8848
Data delayed at least 15 minutes, as of Nov 22 2024 09:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 2 analysts offering 12 month price targets for Jubilant Pharmova Ltd have a median target of 1,331.00, with a high estimate of 1,450.00 and a low estimate of 1,212.00. The median estimate represents a 17.22% increase from the last price of 1,135.50.
High27.7%1,450.00
Med17.2%1,331.00
Low6.7%1,212.00

Dividends

In 2024, Jubilant Pharmova Ltd reported a dividend of 5.00 INR, equaling last years dividend. The 2 analysts covering the company expect dividends of 6.40 INR for the upcoming fiscal year, an increase of 28.00%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On Jul 18, 2024, earnings of 30.44 per share.
The next earnings announcement is expected on May 27, 2025.
Average growth rate+6.60%
Jubilant Pharmova Ltd reported annual 2024 earnings of 4.86 per share on May 29, 2024.
Average growth rate-28.13%
More ▼

Revenue history & estimates in INR

Jubilant Life Sciences Limited had 2nd quarter 2025 revenues of 17.52bn. This missed the 18.40bn estimate of the one analyst following the company. This was 5.14% above the prior year's 2nd quarter results.
Average growth rate+1.29%
Jubilant Life Sciences Limited had revenues for the full year 2024 of 67.03bn. This was 6.70% above the prior year's results.
Average growth rate-5.92%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.